Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Monday, November 8, 2021

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will release its third quarter 2021 financial results on November 8, 2021, after market close. The conference call and webcast will take place at 4:30 PM ET. Interested parties can access the presentation through their website or via dial-in numbers provided. Tricida focuses on developing veverimer, an investigational drug candidate aimed at slowing the progression of chronic kidney disease (CKD) in patients suffering from metabolic acidosis. The VALOR-CKD trial is currently assessing veverimer's efficacy against CKD progression.

Positive

• Upcoming release of Q3 2021 financial results may provide new insights for investors.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its third quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida Conference Call Information

Tricida will host its Third Quarter Financial Results and Business Update Conference Call and webcast on Monday November 8, 2021 at 4:30 pm Eastern Time. The webcast or conference call may be accessed as follows:

Tricida Conference Call

Monday, November 8, 2021

4:30 pm Eastern Time

	Webcast:		IR.Tricida.com
	Dial-In:		(877) 377-5478
	International:		(629) 228-0740
	Conference ID:		8785726

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

What is the date for Tricida's Q3 2021 financial results release?

Tricida's Q3 2021 financial results will be released after market close on November 8, 2021.

When will Tricida hold its conference call for Q3 2021 results?

The conference call for Tricida's Q3 2021 results will occur on November 8, 2021, at 4:30 PM Eastern Time.

How can I access Tricida's Q3 2021 conference call?

You can access Tricida's Q3 2021 conference call through their website at IR.Tricida.com or by dialing (877) 377-5478.

What is veverimer and what is its purpose?

Veverimer is an investigational drug candidate designed to slow CKD progression in patients with metabolic acidosis.

What is the VALOR-CKD clinical trial?

The VALOR-CKD trial is a renal outcomes clinical trial assessing whether veverimer can slow the progression of CKD in patients with metabolic acidosis.